Monocyte- and CD34-Derived Dendritic Cells

How human CD34+ cell progenitors or monocytes can be differentiated in vitro into dendritic cells (DCs) by the combined administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) was first described in 1994. This boosted the enthusiasm for the use of DC vaccination in humans, resulting in the first clinical studies in which monocyte-derived DCs (moDC) were employed as a cellular anticancer vaccine. Since then, numerous—usually small—clinical trials have been performed to demonstrate the efficacy of this approach. After more than one decade, we nowadays know that moDCs can induce anticancer immune responses in a significant number of patients, in particular when both CD4+ and CD8+ T cells are activated, as recently shown by our DC vaccination studies.1 Nevertheless, only a limited number of clinical responses have been observed, yet expectations are high as these responses often are long-lasting.

It remains unclear whether DCs differentiated ex vivo from monocytes or CD34+ cell progenitors are optimal for the induction of potent immune responses.2 The extensive culture period and the agents that are required to differentiate them into DCs might negatively affect immune functions, in particular their capacity to migrate toward T-cell areas in lymph nodes. Therefore, the interest in naturally circulating DCs has risen, despite the fact that these cells are relatively scarce, constituting only about 0.2–1.5% of peripheral blood leukocytes.

Clinical Studies with Natural Plasmacytoid Dendritic Cells

We have embarked on exploiting pDCs that naturally circulate in the peripheral blood for cancer immunotherapy. Although it is well known that inactive intratumoral pDCs are associated with tumor progression, activated, interferon α (IFNα)-producing pDCs can stimulate NK cells and induce antigen-specific T- and B-cell responses. Our finding that vaccines commonly used for the prophylaxis of infectious diseases could simply be used as adjuvants for stimulating pDCs to secrete significant amounts of type I interferons, has opened the door to a new era in cancer immunotherapy.

Abbreviations: DC, dendritic cell; IFNα, interferon α; mDC, myeloid dendritic cell; moDC, monocyte-derived dendritic cell; NK, natural killer; pDC, plasmacytoid dendritic cell(s)
of IFNα has certainly expedited the use of naturally circulating DCs in the clinic.6

About three years ago, we initiated the first human study exploiting pDCs to treat advanced (Stage IV) melanoma patients. Designed as a safety study, we treated 15 patients in three cohorts with dose escalating pDC-based vaccines, ranging from 0.3 to 3 million cells per injection. As the number of cells was low and no data existed on their migratory capacity in vivo, we decided to perform intranodal injections, in order to maximize the possibility to elicit an immune response. Although the trial was not designed to measure clinical efficacy, we obtained some surprising clinical results.7 We observed a consistent improvement in clinical responses when these freshly isolated, naturally circulating DCs were compared with conventional moDCs. Indeed, 7 out of 15 Stage IV melanoma patients are still alive two years after the initiation of treatment. Interestingly, we obtained similar results even with a 10-fold lower dose of cells, demonstrating the potency of natural pDCs. Interestingly, Celli et al. have recently demonstrated that as few as one hundred DCs are needed to elicit a T-cell response, suggesting that perhaps only small amounts of DCs are needed for the induction of antitumor responses in patients.8

**Conclusions**

Altogether, our recent findings indicate that it is worthwhile to further explore the potential of pDCs and other naturally circulating DCs for cancer immunotherapy. It will be interesting to see if also other DC subsets, such as mDCs are equally, or even more, effective than pDCs in this setting.

Another strategy of exploiting these cells for immunotherapy would be to target specific naturally circulating DC subsets in vivo. This would prevent isolation, laborious culturing, and antigen loading ex vivo (Fig. 1). Early studies have demonstrated that antigen-antibody conjugates can target DCs in vivo, resulting in efficient antigen presentation.9 However, if antibody-antigen conjugates are not accompanied by adjuvants, tolerance rather than immune responses might be induced. Therefore, several investigators have embarked on the development of nanoparticles that are coated with antibodies to target naturally circulating DCs and loaded with both antigens and adjuvant(s).10 Preliminary clinical studies based on the targeting of naturally circulating DCs are underway.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

References

1. Aarntrten EH, De Vries IJ, Lestertehuis WJ, Schuurhuis D, Jacobs JG, Bel K, et al. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127.

2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258.

3. Liu VJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106:259-62; PMID:11509173; http://dx.doi.org/10.1016/S0092-8674(01)00456-1.

4. Tel J, Scheibeck G, Sirig SP, Mathan TS, Buschow SI, Lambeck AJ, et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T-cells, despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2012; In press. PMID:23212525; http://dx.doi.org/10.1182/blood-2012-06-435644.

5. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 2012; 120:3936-44; PMID:22966165; http://dx.doi.org/10.1182/blood-2012-06-435941.

6. de Vries IJ, Tel J, Beinzes-Ribas D, Torenisma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol 2011; 48:810-7; PMID:21257206; http://dx.doi.org/10.1016/j.molimm.2010.12.022.
7. Tel J, Aartzen EH, Baba T, Schreiber G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen specific T cell responses and enhance overall survival in melanoma patients. Cancer Res, In press.

8. Celli S, Day M, Müller AJ, Molina-Paris C, Lythe G, Bousso P. How many dendritic cells are required to initiate a T-cell response? Blood 2012; 120:3945-8; PMID:22995897; http://dx.doi.org/10.1182/blood-2012-01-408260.

9. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 2011; 23:12-20; PMID:21269839; http://dx.doi.org/10.1016/j.smim.2011.01.001.

10. Tacken PJ, Zeelenberg IS, Cruz J, van Houw-Kuijer MA, van de Glind G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.org/10.1182/blood-2011-07-367615.